The next revolution in
proton therapy

DynamicARC* is expected to be a new, groundbreaking, treatment modality that allows simultaneous dynamic beam delivery at variable energies while the gantry is rotating. Compared to the current standard of Intensity Modulated Proton Therapy (IMPT) where treatment is delivered in 2-3 static fields, DynamicARC helps target the tumor from multiple directions, enhancing tumor coverage and healthy tissue sparing, and allows faster, sharper and simpler treatment workflows.

Committed to shaping the future of proton therapy, IBA initiated the DynamicARC Consortium in collaboration with leading international clinical centers. IBA is also creating a DynamicARC ecosystem, working closely with IBA Dosimetry, Elekta and RaySearch to seamlessly integrate dosimetry solutions, Oncology Information Systems (OIS) and Treatment Planning Systems (TPS) and bring the full benefits of DynamicARC to clinical practice.

Video file

Radiotherapy evolution from VMAT and IMPT to DynamicARC for precise cancer care

The evolution of radiotherapy for precise cancer care focused on maximizing conformal dose distributions with improved target volume coverage and normal tissue sparing. Conventional radiotherapy benefited from Volumetric Modulated Arc Therapy (VMAT), and the progress continued with the development of IMPT, employing Pencil Beam Scanning (PBS) to further reduce side effects, lower secondary cancer risks and improve patients’
quality of life.1-4 

Today, IBA and its clinical and research partners aim to revolutionize cancer care by developing the first spot-scanning proton arc method, DynamicARC, using the Proteus®ONE system. The feasibility of spot-scanning arc proton treatment has been demonstrated, meeting clinical requirements and significantly reducing per-patient treatment delivery time.5,6 The first DynamicARC irradiation has been recently performed, in engineering mode, at Royal Oak (Corewell Health – formerly William Beaumont Hospital).


Shaping the future of proton therapy
with DynamicARC


Download access

Please fill in the form to download the document.

First name*
Last name*
Job title*

IBA uses and stores cookies and other tracking technologies as specified in the IBA's Cookies Policy to improve your browsing experience on our website, and to understand where our visitors are coming from.

Your information will be collected, stored, and used according to IBA’s Privacy Policy.

Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

IBA is committed to making proton therapy accessible to all patients who could benefit from it, and DynamicARC is an important step on this journey. Download the Solution Paper and discover how DynamicARC could help you deliver sharper, faster and simpler treatments.


    DynamicARC could make treatment sharper by delivering an expected lower integral dose and offering better dose conformity. A study of UMCG** shows that this new modality may increase by 22% the number of patients eligible for proton therapy.7,8


    With an optimized workflow, DynamicARC can be faster than IMPT, allowing for higher patient throughput. Reductions of 58% of the average treatment delivery time per patient, compared to IMPT were achieved, and up to 30% increase in patient throughput.9


    DynamicARC is simpler than IMPT, avoiding complex beam arrangements, with fewer therapist actions such as couch rotations or accessory insertions between fields, simplifying treatment planning and delivery.

DynamicARC may
benefit a wide range of
cancer types

1 / 7
Brain Cancer

DynamicARC could significantly reduce the dose delivered to the hippocampus and cochlea in whole-brain radiotherapy and reduce treatment delivery time compared to VMAT.10,11

Breast Cancer

DynamicARC can further reduce the dose delivered to organs-at-risk (OARs) and the probability of normal tissue complications in patients treated for left-sided whole breast radiotherapy.12

Head & Neck

DynamicARC could significantly spare OARs while providing a similar or better robust target coverage compared with IMPT in the treatment of bilateral head and neck cancer.13

Lung Cancer

DynamicARC could further improve the dosimetric results in locally advanced-stage non-small-cell lung cancer (NSCLC) and potentially be implemented into routine clinical practice. It could also enhance normal tissue sparing and feasibility in lung stereotactic body radiotherapy (SBRT). 14,15

Prostate Cancer

DynamicARC could provide a more robust and improved plan quality and reduce the beam delivery time to a practical, achievable time.16

Spine Metastases

DynamicARC further improved the target coverage conformity and robustness compared to IMPT and would be more efficient, while providing equivalent and better dosimetric plan quality, compared to VMAT for spine stereotactic body radiosurgery (SBRS). 17

Across indications

DynamicARC allows to optimize plan quality and delivery time, potentially increasing patient throughput and reducing operation costs,18-21 and could maximize the dose-averaged linear energy transfer (LETd) distribution inside the target while sparing OARs,22 and better adapt to patient conditions and clinical resources available.23

Any questions?

IBA’s leadership in proton therapy#


patients treated with Proteus advanced technology


of all patients treated with IBA proton therapy equipment worldwide


proton therapy treatment centers installed and in development


proton therapy treatment rooms


years of leadership in the field


IMPT: intensity modulated proton therapy
LET: linear energy transfer
NSCLC: non-small-cell lung cancer 
OARs: organs-at-risk 
OIS: oncology information systems 
PBS: pencil beam scanning 
SBRS: stereotactic body radiosurgery 
SBRT: stereotactic body radiotherapy 
TPS: treatment planning systems 
UMCG: University Medical Center Groningen 
VMAT: volumetric modulated arc therapy 

*DynamicARC® and ConformalFLASH® are registered brands of IBA’s Proton Therapy which are currently under research and development.
DynamicARC® and ConformalFLASH® will be available for sale when regulatory clearance is received. Due to a continuous research and
development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior
notice. Some features are under development and may be subject to review by competent authorities. 

** Study performed in oropharyngeal cancer patients. 

# Data from IBA & PTCOG 2022, consulted in November 2023

1. Teoh M et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84(1007): 967-9 
2. Hu M et al. Proton beam therapy for cancer in the era of precision medicine. J Hematol Oncol. 2018;11(1):136. 
3. Holliday EB et al. Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of IntensityModulated Proton Therapy and Intensity-Modulated Photon Therapy. Int J Part Ther. 2015;2(1):19–28. 
4. Yuan TZ, et al. New frontiers in proton therapy: applications in cancers. Cancer Commun (2019) 39:61 
5. Li X, et al. The First Prototype of Spot-Scanning Proton Arc Treatment Delivery. Radiother Oncol. 2019;137:130–36. 
6. Ding X, et al. The first modeling of the spot-scanning proton arc (SPArc) delivery sequence and investigating its efficiency improvement. Int J Part Ther. 2022;8(4):97. 
7. de Jong B et al. Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model-based clinic. Radiother Oncol. 2023:184;109670. 
8. de Jong B et al. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients. Med Phys. 2023;50(3):1305-1317. 
9. Liu G et al. Development of a standalone delivery sequence model for proton arc therapy. Med Phys. 2023. doi: 10.1002/mp.16879. 
10. Ding X et al. Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy. Acta Oncol. 2019;58(4):483-490. 
11. Chang S et al. Redefine the Role of Spot-Scanning Proton Beam Therapy for the Single Brain Metastasis Stereotactic Radiosurgery. Front Oncol. 2022;12:804036. 
12. Chang S et al. Feasibility study: spot-scanning proton arc therapy (SPArc) for left-sided whole breast radiotherapy. Radiat Oncol. 2020;15:232. 
13. Liu G et al. Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study. Radiat Oncol. 2020;15(1):21. 
14. Li X et al. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy. Radiat Oncol. 2018;13(1):35. 
15. Liu G et al. Lung Stereotactic Body Radiotherapy (SBRT) Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study. Front Oncol. 2021;11:664455. 
16. Ding X et al. Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol. 2018;57(3):435-437. 
17. Liu G et al. Is proton beam therapy ready for single fraction spine SBRS? - a feasibility study to use spot-scanning proton arc (SPArc) therapy to improve the robustness and dosimetric plan quality. Acta Oncol. 2021;60(5):653-657. 
18. Liu G et al. A novel energy sequence optimization algorithm for efficient spot-scanning proton arc (SPArc) treatment delivery. Acta Oncol. 2020;59(10):1178-1185. 
19. Zhao L et al. An evolutionary optimization algorithm for proton arc therapy. Phys Med Biol. 2022;67(16). 
20. Zhao L et al. The first direct method of spot sparsity optimization for proton arc therapy. Acta Oncol. 2023;62(1):48-52. 
21. Engwall E et al. Fast robust optimization of proton PBS arc therapy plans using early energy layer selection and spot assignment. Phys Med Biol. 2022;67(6). 
22. Li X et al. Linear Energy Transfer Incorporated Spot-Scanning Proton Arc Therapy Optimization: A Feasibility Study. Front Oncol. 2021;11:698537. 
23. Wuyckens S et al. Bi-criteria Pareto optimization to balance irradiation time and dosimetric objectives in proton arc therapy. Phys Med Biol. 2022;67(24).

Cookies policy

If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.

Manage your cookie preferences

Respect for your privacy is still a priority for us at IBA.

Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.

Cookies policies